{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:27:14Z","timestamp":1790083634521,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.phrs.2021.105565","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T12:20:22Z","timestamp":1616070022000},"page":"105565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients"],"prefix":"10.1016","volume":"167","author":[{"given":"Wieteke","family":"Kleinherenbrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizal","family":"Nakhsbandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke I.","family":"Roodnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2021.105565_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Valganciclovir solid organ transplant study group. efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.phrs.2021.105565_bib2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/01.TP.0000142619.01510.A5","article-title":"Valganciclovir solid organ transplant study group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients","volume":"78","author":"Freeman","year":"2004","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.phrs.2021.105565_bib3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.phrs.2021.105565_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13052","article-title":"Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"15","author":"van den Hoogen","year":"2015","journal-title":"Am. J. Transplant."},{"issue":"19","key":"10.1016\/j.phrs.2021.105565_bib5","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group","volume":"340","author":"Lowance","year":"1999","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2021.105565_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000491558","article-title":"Delayed graft function: the AKI of kidney transplantation","volume":"140","author":"Mannon","year":"2018","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.phrs.2021.105565_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1469-0691.2000.00014.x","article-title":"Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis","volume":"6","author":"Piketty","year":"2000","journal-title":"Clin. Microbiol. Infect."},{"issue":"6","key":"10.1016\/j.phrs.2021.105565_bib8","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1600-6143.2008.02220.x","article-title":"Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients","volume":"8","author":"Chamberlain","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.phrs.2021.105565_bib9","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1128\/AAC.00375-13","article-title":"Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir","volume":"57","author":"Trevillyan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.phrs.2021.105565_bib10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Valganciclovir solid organ transplant study group. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.phrs.2021.105565_bib11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s40262-018-0638-5","article-title":"Valganciclovir pharmacokinetics in patients receiving oral prophylaxis following kidney transplantation and model-based predictions of optimal dosing regimens","volume":"57","author":"T\u00e4ngd\u00e9n","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.phrs.2021.105565_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz215","article-title":"Risk factors for failure of primary (Val)ganciclovir prophylaxis against cytomegalovirus infection and disease in solid organ transplant recipients","volume":"6","author":"Khurana","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2021.105565_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13125","article-title":"Clinical outcomes of valganciclovir prophylaxis in high\u2010risk (D+\/R\u2212) renal transplant recipients experiencing delayed graft function","volume":"21","author":"Freedman","year":"2019","journal-title":"Transpl. Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2021.105565_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?","volume":"26","author":"Scott","year":"2004","journal-title":"Ther. Drug Monit."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:26:24Z","timestamp":1760912784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821001493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":14,"alternative-id":["S1043661821001493"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105565","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105565"}}